» Articles » PMID: 21413015

An Intact Retinoblastoma Protein-binding Site in Merkel Cell Polyomavirus Large T Antigen is Required for Promoting Growth of Merkel Cell Carcinoma Cells

Overview
Journal Int J Cancer
Specialty Oncology
Date 2011 Mar 18
PMID 21413015
Citations 114
Authors
Affiliations
Soon will be listed here.
Abstract

Merkel cell carcinoma (MCC) is a highly aggressive skin cancer that frequently harbours Merkel cell polyomavirus (MCV) DNA integrated in the genome of the tumor cells. In our study, we elaborate our recent finding that MCV-positive MCC cell lines require the expression of the viral T antigens (TA). Indeed, in a xeno-transplantation model, we prove that TA expression is essential also in an in vivo situation, as knock down of TA leads to tumor regression. Moreover, rescuing TA short hairpin RNA (shRNA)-treated MCV-positive MCC cells by ectopic expression of shRNA-insensitive TAs clearly demonstrates that the observed effect is caused by TA knockdown. Notably, introduction of a mutation in the LTA protein interfering with LTA binding to the retinoblastoma protein (RB) ablated this rescue. The importance of this interaction was further confirmed as LTA-specific knockdown leads to explicit cell growth inhibition. In summary, the presented data demonstrate that established MCV-positive MCC tumors critically depend on TA expression, in particular the LTA and RB interaction, for sustained tumor growth. Consequently, interference with LTA/RB interaction appears as promising strategy to treat MCC.

Citing Articles

The Role of the Large T Antigen in the Molecular Pathogenesis of Merkel Cell Carcinoma.

Myrda J, Bremm F, Schaft N, Dorrie J Genes (Basel). 2024; 15(9).

PMID: 39336718 PMC: 11431464. DOI: 10.3390/genes15091127.


Polyomavirus ALTOs, but not MTs, downregulate viral early gene expression by activating the NF-κB pathway.

Salisbury N, Amonkar S, Landazuri Vinueza J, Carter J, Roman A, Galloway D Proc Natl Acad Sci U S A. 2024; 121(34):e2403133121.

PMID: 39141346 PMC: 11348336. DOI: 10.1073/pnas.2403133121.


Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models.

Pedersen E, Verhaegen M, Joseph M, Harms K, Harms P Front Oncol. 2024; 14:1413793.

PMID: 39136002 PMC: 11317257. DOI: 10.3389/fonc.2024.1413793.


Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell Carcinoma.

Asano Y, Veatch J, McAfee M, Bakhtiari J, Lee B, Martin L medRxiv. 2024; .

PMID: 39006423 PMC: 11245074. DOI: 10.1101/2024.07.01.24309780.


Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.

Sol S, Boncimino F, Todorova K, Waszyn S, Mandinova A Int J Mol Sci. 2024; 25(13).

PMID: 39000164 PMC: 11241167. DOI: 10.3390/ijms25137056.